The opening line of an NACDS-authored article in the January 2, 2017, edition of Chain Drug Review says it all. “I will spare you the introductory paragraph that attempts eloquence,” writes NACDS President & CEO Steven C. Anderson, IOM, CAE. “Let’s get right to the point. In NACDS’ view, 2017 could be one of the most pivotal years in healthcare policy and in pharmacy patient care.”
NACDS already is waging a two-front campaign related to the ACA.
While NACDS’ article on the policy outlook for the coming year has become somewhat of an annual tradition, its content this time around is decidedly untraditional. For example, Anderson noted the importance of continuing to bird-dog the implementation of pharmacy provisions of the Affordable Care Act and its subsequent Executive Branch rules, while at the same time advocating for pharmacy’s perspective amid emerging efforts to somehow repeal and replace the law.
“NACDS already is waging a two-front campaign related to the ACA,” Anderson noted.
The article also describes NACDS’ work on issues related to provider status for pharmacists; scope of practice; TRICARE and more. In addition, Anderson urges participation in NACDS RxIMPACT grassroots programs, which have become essential to telling pharmacy’s story to government leaders and to earning progress on a pro-patient and pro-pharmacy agenda.
Calling on pharmacy advocates to match the amazing results of the 2016 NACDS RxIMPACT Day on Capitol Hill – when they met with 90 percent of the U.S. Congress – Anderson declared that “pharmacy’s engagement is needed to defend and advance pharmacy patient care.”
The 2017 NACDS RxIMPACT Day on Capitol Hill will be held March 14 and 15 in Washington, D.C.
The article that starts with a plain-spoken assessment of the public policy stakes in 2017 concludes with similar candor regarding the importance of NACDS’ flagship grassroots advocacy event: “For the good of your business and the patients you serve, you need to be there – perhaps like never before.”
